Moderna shares plunge after leak of cancer vaccine data despite positive results
Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty expectations
Coverage across the spectrum
How we rate outletsThe story so far
- Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Drug Makers Report.
- Moderna shares sink after leaked cancer data missed expectations.
Who's reporting it
All 8 sources- UTUS Top News and Analysis (US)Center
Moderna shares plunge after cancer vaccine data leaks — despite positive results
- Financial TimesFT
Financial TimesCenterModerna shares sink after leaked cancer data missed expectations
- CNNCNN
CNNLeftExperimental mRNA vaccine cuts risk melanoma returns by 42%
- WSJWSJWSJCenter
Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media
- The New York TimesTN
The New York TimesLeftCancer Vaccine Cuts the Risk of Melanoma Recurrence, Drug Makers Report
Timeline
5h ago
The New York Times: Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Drug Makers Report
5h ago
Financial Times: Moderna shares sink after leaked cancer data missed expectations
5h ago
WSJ: Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media
5h ago
US Top News and Analysis (US): Moderna released full data on its closely watched cancer vaccine developed with Merck.
5h ago
CNN: When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial i
4h ago
US Top News and Analysis (US): Moderna's stock fell even though the full data, released later Thursday, appeared positive based on Wall Street expectations ahead of the re
2h ago
Financial Times: Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty expectations
2h ago
US Top News and Analysis (US): Moderna released full data on its closely watched cancer vaccine developed with Merck.
More in Health
Residents in eastern Congo cling to hope as a new Ebola treatment trial begins
Multiple outlets • 2h ago
GENEVA, Switzerland—The first clinical trial of an Ebola vaccine in the outbreak gripping the Democratic Republic of Congo began Friday, the head of the World Health Organization said. The DR Congo‘s worst-ever Ebola outbreak has passed the 9,700-case mark, with the number of deaths exceeding 4,600. Among the many problems facing the response is the lack of any approved vaccines or treatments for the Bundibugyo species of Ebola behind the epidemic. Ervebo, a vaccine approved for use against…
13 sources
‘It’s never going to get better than this’: Edendork hero Niall Morgan revels in first ever Tyrone SFC triumph
Multiple outlets • 4h ago
Edendork have beaten Errigal Ciaran 1-14 to 1-13 in the replayed Tyrone Senior Football Final in Omagh this evening. Niall Morgan’s two-point free-kick in injury time handed the underdogs their first ever Tyrone title in dramatic circumstances at Healy Park. Edendork, who forced a replay after a late Darren McCurry two-pointer last weekend, led…
6 sources
Kenya announces second Ebola death, says ‘no evidence’ of community spread
Multiple outlets • 4h ago
NAIROBI, Kenya (AP) — Kenya’s Health Ministry announced the country's second Ebola death Friday, saying a 65-year-old woman who was a close relative of the first patient died after developing symptoms while in quarantine.
3 sources
Brute jailed for killing pub-goer in Christmas Eve brawl - just hours after finding out victim was his biological dad
Multiple outlets • 5h ago
Steven Shevels died after his head hit the concrete floor of a beer garden on Christmas Eve, with a court finding his own biological son was the one who pushed…
4 sources
Man extradited from Poland over body found in a cabinet in NSW
Multiple outlets • 2h ago
3 sources
DRC begins new vaccine trial as outbreak kills over 4,600
Multiple outlets • 3h ago
The trial, named Tumaini, which means “hope” in Swahili, will assess vaccine candidates designed to protect against the Bundibugyo virus, for which no vaccine has been…
2 sources
Reader Discussion
Loading comments…